Samsung Biologics’ U.S. subsidiary signed a definitive agreement to acquire Human Genome Sciences’ Rockville, Maryland manufacturing site from GSK for $280 million, marking Samsung’s first U.S. manufacturing foothold. The facility includes two cGMP plants with roughly 60,000 L capacity and will remain operational under Samsung, which plans further investments to expand capacity and upgrade technology. The deal preserves more than 500 jobs and strengthens Samsung Biologics’ global biologics manufacturing footprint as demand for contract development and manufacturing services (CDMO) and domestic capacity rises.